A categorization of metal anticancer compounds based on their mode of action.

The development of new metal anticancer compounds is a challenge for inorganic chemists. We have to face the fact that four decades of research in this field have only produced a small number of clinically used compounds, most often developed through serendipity rather than through rational chemical design. Nevertheless, by virtue of the wealth of knowledge acquired in these years, medicinal inorganic chemistry is probably mature for making significant steps forward and there are great expectations for future developments. With the aim of contributing to the rationalization of this field, we suggest here a categorization of metal anticancer compounds into five classes based on their mode of action: (i) the metal has a functional role, i.e. it must bind to the biological target; (ii) the metal has a structural role, i.e. it is instrumental in determining the shape of the compound and binding to the biological target occurs through non-covalent interactions; (iii) the metal is a carrier for active ligands that are delivered in vivo; (iv) the metal compound is a catalyst; and (v) the metal compound is photoactive and behaves as a photo-sensitizer. Selected examples for each category are given. The few metal anticancer drugs that are in clinical use are all believed to be functional compounds. Our classification, that is clearly focused on the metal compound and is independent from the nature of its bio-target(s)-most often still unknown-has the purpose of providing an intellectual tool that might be helpful in the rational development of new drugs.

[1]  J. Reedijk Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design , 2009 .

[2]  J. Navarro,et al.  Cyclic assemblies formed by metal ions, pyrimidines and isogeometrical heterocycles : DNA binding properties and antitumour activity , 2009 .

[3]  P. Sadler,et al.  Photoinduced reactions of cis,trans,cis-[Pt(IV)(N3)2(OH)2(NH3)2) with 1-methylimidazole. , 2009, Chemistry.

[4]  A. Casini,et al.  Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. , 2008, Journal of medicinal chemistry.

[5]  W. Berger,et al.  KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.

[6]  Michael J. Rose,et al.  Photoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors. , 2008, Coordination chemistry reviews.

[7]  P. Sadler,et al.  Catalytic organometallic anticancer complexes , 2008, Proceedings of the National Academy of Sciences.

[8]  Ingo Ott,et al.  Cellular Uptake, Cytotoxicity, and Metabolic Profiling of Human Cancer Cells Treated with Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(NN)]Cl2 with NN=bpy, phen, dpq, dppz, and dppn , 2008, ChemMedChem.

[9]  N. Moitessier,et al.  A platinum supramolecular square as an effective G-quadruplex binder and telomerase inhibitor. , 2008, Journal of the American Chemical Society.

[10]  Michael J. Rose,et al.  Sensitization of ruthenium nitrosyls to visible light via direct coordination of the dye resorufin: trackable NO donors for light-triggered NO delivery to cellular targets. , 2008, Journal of the American Chemical Society.

[11]  R. Webster,et al.  Similar biological activities of two isostructural ruthenium and osmium complexes. , 2008, Chemistry.

[12]  B. Keppler,et al.  Electron-transfer activated metal-based anticancer drugs , 2008 .

[13]  P. Dyson,et al.  The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells. , 2008, Angewandte Chemie.

[14]  Long Jiang,et al.  Single oxygen-mediated DNA photocleavage of a di-bithiazolyl ruthenium(II) complex [Ru(btz) 2 (dppz)] 2+ , 2008 .

[15]  R. Eldik,et al.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin , 2008, JBIC Journal of Biological Inorganic Chemistry.

[16]  P. Sadler,et al.  New trends for metal complexes with anticancer activity. , 2008, Current opinion in chemical biology.

[17]  L. Juillerat-Jeanneret,et al.  Ruthenium porphyrin compounds for photodynamic therapy of cancer. , 2008, Journal of medicinal chemistry.

[18]  M. Jakupec,et al.  Antitumour metal compounds: more than theme and variations. , 2008, Dalton transactions.

[19]  P. Dyson Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development , 2007 .

[20]  P. Sadler,et al.  The design of organometallic ruthenium arene anticancer agents , 2007 .

[21]  A. Vessières,et al.  Ferrocifens and ferrocifenols as new potential weapons against breast cancer , 2007 .

[22]  T. Hambley Developing new metal-based therapeutics: challenges and opportunities. , 2007, Dalton transactions.

[23]  P. Sadler,et al.  Using coordination chemistry to design new medicines , 2007 .

[24]  J. Navarro,et al.  Design and non-covalent DNA binding of platinum(II) metallacalix[4]arenes. , 2007, Chemistry.

[25]  B. Kariuki,et al.  Dinuclear ruthenium(II) triple-stranded helicates: luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines. , 2007, Angewandte Chemie.

[26]  R. Eldik,et al.  Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution , 2007, JBIC Journal of Biological Inorganic Chemistry.

[27]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[28]  J. Aldrich-Wright,et al.  Chiral Platinum(II) Metallointercalators with Potent in vitro Cytotoxic Activity , 2007, ChemMedChem.

[29]  R. Webster,et al.  Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand. , 2007, Organic & biomolecular chemistry.

[30]  F. Avilés,et al.  DNA interaction and antiproliferative behavior of the water soluble platinum supramolecular squares [(en)Pt(N-N)]4(NO3)8 (en=ethylenediamine, N-N=4,4'-bipyridine or 1,4-bis(4-pyridyl)tetrafluorobenzene). , 2007, Journal of inorganic biochemistry.

[31]  T. Hambley,et al.  Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. , 2007, Chemistry.

[32]  A. Bergamo,et al.  Ruthenium complexes can target determinants of tumour malignancy. , 2007, Dalton transactions.

[33]  P. Sadler,et al.  Transplatin is cytotoxic when photoactivated: enhanced formation of DNA cross-links. , 2006, Journal of medicinal chemistry.

[34]  N. Farrell,et al.  A third mode of DNA binding: Phosphate clamps by a polynuclear platinum complex. , 2006, Journal of the American Chemical Society.

[35]  P. Dyson,et al.  Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy , 2006 .

[36]  R. Scopelliti,et al.  Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. , 2006, Inorganic chemistry.

[37]  B. Elias,et al.  Photo-reduction of polyazaaromatic Ru(II) complexes by biomolecules and possible applications , 2006 .

[38]  P. Dyson,et al.  Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.

[39]  T. Boulikas,et al.  Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. , 2006, Anticancer research.

[40]  N. Metzler‐Nolte,et al.  New principles in medicinal organometallic chemistry. , 2006, Angewandte Chemie.

[41]  S. Knapp,et al.  Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.

[42]  I. Usón,et al.  Molecular recognition of a three-way DNA junction by a metallosupramolecular helicate. , 2006, Angewandte Chemie.

[43]  Katherine H Thompson,et al.  Metal complexes in medicinal chemistry: new vistas and challenges in drug design. , 2006, Dalton transactions.

[44]  N. Farrell,et al.  Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. , 2005, Inorganic chemistry.

[45]  S. Elmroth,et al.  Light-induced anticancer activity of [RuCl2(DMSO)4] complexes. , 2005, Journal of medicinal chemistry.

[46]  T. Boulikas,et al.  Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. , 2005, Anticancer research.

[47]  P. Dyson,et al.  In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. , 2005, Journal of medicinal chemistry.

[48]  F. Noor,et al.  A cobaltocenium-peptide bioconjugate shows enhanced cellular uptake and directed nuclear delivery. , 2005, Angewandte Chemie.

[49]  A. Vessières,et al.  Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. , 2005, Journal of medicinal chemistry.

[50]  N. Farrell,et al.  Unique cooperative binding interaction observed between a minor groove binding Pt antitumor agent and Hoechst dye 33258. , 2005, Inorganic chemistry.

[51]  K. Szaciłowski,et al.  Bioinorganic photochemistry: frontiers and mechanisms. , 2005, Chemical reviews.

[52]  C. S. Allardyce,et al.  Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. , 2005, Journal of the American Chemical Society.

[53]  A. Bergamo,et al.  Ruthenium antimetastatic agents. , 2004, Current topics in medicinal chemistry.

[54]  Colin G. Barry,et al.  Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. , 2004, Current topics in medicinal chemistry.

[55]  M. Jakupec,et al.  Gallium in cancer treatment. , 2004, Current topics in medicinal chemistry.

[56]  Douglas S. Williams,et al.  An organometallic inhibitor for glycogen synthase kinase 3. , 2004, Journal of the American Chemical Society.

[57]  A. Mikhailovsky,et al.  Photochemical production of nitric oxide via two-photon excitation with NIR light. , 2004, Journal of the American Chemical Society.

[58]  M. Jakupec,et al.  Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-κ2N, O)platinum(II): a representative of novel pH sensitive anticancer platinum complexes , 2004 .

[59]  D. Magde,et al.  Synthesis and photochemical properties of a novel iron-sulfur-nitrosyl cluster derivatized with the pendant chromophore protoporphyrin IX. , 2004, Inorganic chemistry.

[60]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[61]  J. Collins,et al.  DNA binding and biological activity of some platinum(II) intercalating compounds containing methyl-substituted 1,10-phenanthrolines. , 2004, Dalton transactions.

[62]  S. Lippard,et al.  Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. , 2004, Chemistry and Biology.

[63]  Jim A. Thomas,et al.  Kinetically inert transition metal complexes that reversibly bind to DNA. , 2003, Chemical Society reviews.

[64]  Y. Sohn,et al.  Synthesis, biodistribution and antitumor activity of hematoporphyrin-platinum(II) conjugates. , 2003, Bioorganic & medicinal chemistry.

[65]  Jan Reedijk,et al.  New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Sadler,et al.  Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. , 2003, Journal of the American Chemical Society.

[67]  P. A. Lay,et al.  Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized , 2002 .

[68]  M. Dicato,et al.  In vitro inhibition of gene transcription by novel photo-activated polyazaaromatic ruthenium(II) complexes. , 2002, Chemical communications.

[69]  C. Lottner,et al.  Hematoporphyrin-derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity. , 2002, Journal of medicinal chemistry.

[70]  C. Lottner,et al.  Soluble tetraarylporphyrin-platinum conjugates as cytotoxic and phototoxic antitumor agents. , 2002, Journal of medicinal chemistry.

[71]  P. Sadler,et al.  Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. , 2002, Journal of the American Chemical Society.

[72]  Jurek Dobrucki,et al.  Interaction of oxygen-sensitive luminescent probes Ru(phen)32+ and Ru(bipy)32+ with animal and plant cells in vitro , 2001 .

[73]  C. Che,et al.  Platinum(II) Complexes of Dipyridophenazine as Metallointercalators for DNA and Potent Cytotoxic Agents against Carcinoma Cell Lines , 1999 .

[74]  D. Odom,et al.  Recognition and reaction of metallointercalators with DNA. , 1999, Chemical reviews.

[75]  M J Clarke,et al.  Non-platinum chemotherapeutic metallopharmaceuticals. , 1999, Chemical reviews.

[76]  H. R. Palmer,et al.  Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. , 1998, Anti-cancer drug design.

[77]  C. Biot,et al.  Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. , 1997, Journal of medicinal chemistry.

[78]  C. Moucheron,et al.  Photophysics of Ru(phen)2(PHEHAT)2+: A Novel “Light Switch” for DNA and Photo-oxidant for Mononucleotides , 1997 .

[79]  J. Kelly,et al.  Ruthenium(II) complexes with 1,4,5,8,9,12-hexaazatriphenylene and 1,4,5,8-tetraazaphenanthrene ligands: Key role played by the photoelectron transfer in DNA cleavage and adduct formation , 1995 .

[80]  W. Denny,et al.  Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. , 1993, Journal of medicinal chemistry.

[81]  W. Eitel Die nutzbaren Mineralien mit Ausnahme der Erze und Kohlen. Von Br. Dammer. 2. neubearbeitete Auflage. I. Band. Stuttgart 1927. Verlag von F. Enke. XX, 554 S. Mit 66 Abb , 1927 .

[82]  J. Reedijk Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes , 2008 .

[83]  L. Juillerat-Jeanneret,et al.  Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy , 2008, JBIC Journal of Biological Inorganic Chemistry.

[84]  K. Flaherty,et al.  An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.

[85]  A. Vessières,et al.  Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. , 2005, Angewandte Chemie.

[86]  R. Knuechel,et al.  Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates. , 2004, Cancer letters.

[87]  A. Bergamo,et al.  Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. , 2002, European journal of cancer.

[88]  C. S. Allardyce,et al.  [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .

[89]  W. Denny,et al.  Design and synthesis of cobalt(III) nitrogen mustard complexes as hypoxia selective cytotoxins. The X-ray crystal structure of bis(3-chloropentane-2,4-dionato)(RS-N,N′-bis(2-chloroethyl)ethylenediamine)cobalt(III) perchlorate, [Co(Clacac)2(bce)]ClO4 , 1991 .